Heart Failure Biomarker Detection With Non-Invasive Oral Sampling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current disease detection methods are inefficient, costly, and not disease-specific, often occurring too late to be effective, lacking precision in identifying risk factors for conditions like heart failure, and failing to provide clinically actionable information without invasiveness.
Innovation Solution
The use of biomarkers such as AMPN, AMD, CALM3, KI21A, ACBP, IGA2, and S10A7 polypeptides to detect heart failure risk, combined with machine learning models and oral sample collection devices, allows for early identification of heart failure risk through non-invasive means, enabling personalized treatment strategies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current disease detection methods (echocardiograph, blood tests, cardiopulmonary exercise) are used to detect heart failure risk, then diagnostic accuracy can be improved, but invasiveness and cost increase
Solution Approach 1:
The patent replaces invasive mechanical diagnostic procedures (echocardiography, blood draws, exercise stress tests) with a non-invasive optical detection system that uses light to measure biomarker concentrations in interstitial fluid through the skin, eliminating the need for physical intrusion into the body
Solution Approach 2:
The patent introduces interstitial fluid as an intermediary medium that contains biomarkers reflecting cardiac stress, allowing indirect measurement of heart function without direct contact with cardiac tissue or blood vessels, thus achieving accurate diagnosis non-invasively
2Loss of information
If current disease detection methods are used, then comprehensive diagnostic information can be obtained, but time and cost efficiency deteriorate
Solution Approach 1:
The patent enables preliminary detection of heart failure risk by measuring biomarker levels in interstitial fluid before clinical symptoms manifest, allowing early intervention and treatment planning without requiring time-consuming confirmatory tests or hospital visits
Solution Approach 2:
The patent extracts only the essential diagnostic information (biomarker concentrations in interstitial fluid) needed for heart failure risk assessment, eliminating the need for comprehensive but time-consuming battery of traditional diagnostic tests
3Reliability
If traditional biomarker panels are used for heart failure detection, then disease-specific detection can be improved, but measurement precision and reliability deteriorate due to lack of validation over large populations
Solution Approach 1:
The patent changes the measurement parameter from traditional serum biomarkers to interstitial fluid biomarkers, which better reflect real-time cardiac stress and provide more precise and reliable detection across diverse populations and clinical settings
Data Source
AI summary
Disclosed herein are methods and compositions for the detection of biomarkers for cardiac diseases. Disclosed herein are sample collection devices comprising detection devices for heart failure. Disclosed herein are methods of detecting, monitoring, preventing, or treating heart failure.